Please ensure Javascript is enabled for purposes of website accessibility

Here's Why MacroGenics Is Tumbling 17.3% Today

By Todd Campbell – Updated May 29, 2020 at 12:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Traders are exiting the stock as the ASCO 2020 conference gets underway.

What happened

MacroGenics (MGNX 1.47%) shares are falling 17.3% as of 12:15 p.m. EST on Friday. The drop coincides with the release of the company's presentations at the annual American Society of Clinical Oncology meeting, and it follows a surge in its share price earlier this month.

So what

The ASCO conference is highly anticipated, and historically, investors have bought shares in stocks presenting at the conference ahead of time, hoping for a short-term pop. That strategy worked out well for investors in MacroGenics, which saw its share price triple in the past month because of positive news regarding its lead drug candidate, margetuximab, and promising data for MGD013 and MGC018 reported in its ASCO abstracts on May 11.

An upward arrow with a break in it that causes it to turn lower

IMAGE SOURCE: GETTY IMAGES.

On May 5, the biotech company said final overall survival (OS) data for its phase 3 SOPHIA study of margetuximab in HER2-positive metastatic breast cancer will be reported this year, and it anticipates a Food and Drug Administration go/no-go decision based on previously reported progression-free survival data in December 2020.

That news, which sent shares skyrocketing 231% on May 6th, was followed a week later by abstracts highlighting promising efficacy to be presented at ASCO for two earlier-stage drugs in its pipeline. The abstract for MGD013, an anti-Lag3 & PD-1 bispecific monoclonal antibody in phase 1 trials for metastatic breast cancer, showed a 40% overall response rate in HER2+ solid-tumor patients also taking margetuximab. Separately, the abstract for MGC018, an anti-B7-H3 antibody drug conjugate, showed that it reduced prostate-specific antigen, or PSA, by over 50% in five of seven patients with metastatic castration-resistant prostate cancer.

Now what

The absence of significantly different data in the official presentations at ASCO suggest that today's drop in MacroGenics shares is a classic example of "sell the news." Investors can't be blamed for pocketing some of their profit given how much shares are up this month; however, today's drop could be a good time for long-term, risk-tolerant biotech investors to buy shares.

On May 28, the FDA said it doesn't plan on convening an advisory committee to weigh in on margetuximab prior to making its decision, suggesting an OK may be coming later this year. Because margetuximab is a reengineered version of the blockbuster drug Herceptin, and it outperformed Herceptin in PFS, it could be a top seller if it nabs approval, especially if overall survival data impresses later this year. The intriguing early-stage data for MGD013 and MGC018 also shows that MacroGenics has other drugs targeting big indications in the wings, making the company more attractive.

Nevertheless, since we could get a disappointing read-out on margetuximab's overall survival, and there's always the risk of an FDA rejection, this company is best suited for investors who can tolerate a lot of risk.

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MacroGenics, Inc. Stock Quote
MacroGenics, Inc.
MGNX
$3.46 (1.47%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.